Evaluation of economic burden with biologic treatments in Crohn’s disease patients: A mirror image study using an insurance database in Japan

Celine Miyazaki1,*, Nagano Katsumasa2, Kuan Chih Huang3, Yan Fang Liu4

1 Health Economics Department, Janssen Pharmaceutical K.K., Tokyo, Japan, 2 Medical Affairs Department, Janssen Pharmaceutical K.K., Tokyo, Japan, 3 Janssen Research & Development Epidemiology, Taipei, Taiwan, 4 Global Epidemiology, Janssen Research & Development, Singapore, Singapore

* These authors contributed equally to this work.
+ CMiyazaki@its.jnj.com

Abstract

Biologics are recommended in Japan to treat moderate to severe Crohn’s Disease (CD). Although CD is associated with high direct costs in Japan, updated information after ustekinumab’s approval is unavailable. We aimed to evaluate the healthcare resource utilization (HRU) and associated direct costs from the payer’s perspective in Japan. Claims data (2010–2018) were retrospectively analyzed to identify patients with CD. HRU and associated costs were evaluated for 12 months before and after biologic initiation and followed-up till 36 months post-initiation. Outcomes were reported using descriptive statistics. Among the included patients (n = 3,496), 1,783 were on biologics and 1,713 were on non-biologics. Mean (SD) age was 36.4 (13.2) years and patients were predominantly male (76.1%). Patients aged 18–39 years were affected with CD the most (55.3%). Biologic initiation was associated with a reduction in inpatient stay, length of stay, outpatient visits, and associated costs; and an increase in pharmacy costs and total costs after 12 months. Extended follow-up showed a decreasing trend in HRU and costs till 24 months but an increase after 36 months. These findings demonstrated reduction in clinical burden and slight increase in economic burden with biologics. However, indirect costs also need to be evaluated.

Introduction

Crohn’s disease (CD) is a chronic, progressive, inflammatory gastrointestinal disease leading to bowel damage and disability due to complications such as bowel strictures, abscesses, or fistulas [1, 2]. The number of individuals affected with CD in Japan was reported to be 40,000 in 2013 by the Japan Intractable Diseases Information Center [3] and 70,700 in 2014 based on a nationwide survey by Murakami et al [4]. Additionally, the prevalence of CD in Japan has been increasing with time from 0.88 per 100,000 in 1965 [5] to 55.6 per 100,000 in 2014 [4].
As the goal of CD treatment is prevention of progression, symptom control, and reduction in risk of complications, effective long-term management and treatment persistence is essential [6]. The standard of care for CD in Japan includes corticosteroids, enteral nutrition therapy, 5-aminosalicylic acid (5-ASA), immunomodulators, biologics, and surgery depending on disease severity and presence/absence of complications [7, 8]. Biologics are recommended for patients with moderate to severe CD, if steroids and/or nutritional therapy is not effective [7]. Infliximab was the first biologic to be approved for CD by Japan in 2002 [9], followed by adalimumab in 2010 [10] and ustekinumab in 2017 [11]. The advent of these biologics have led to improved long-term prognosis; reduction in relapse rate, requirement of surgery, and issues related to steroid discontinuation; as well as enabled patients to receive treatment in an outpatient setting [7, 12, 13].

The introduction of the Intractable Disease Health Care Act in Japan allowed patients with rare diseases such as CD to receive financial assistance in lieu of authorizing usage of their data for research [14]. Such subsidies are provided to patients with a predetermined severity level as defined by the disease severity classification and who face impediments in their daily life [15]. However, as 331 diseases including CD are covered under the Act as of 2018 [15], balancing adequate healthcare coverage with available funds is a challenge. Moreover, the rapidly aging population (27.7% aged >65 years) and simultaneous reduction in labor force has strained the healthcare sector, since taxes obtained from working individuals for public health programs are inadequate to sustain coverage for the whole population [16].

As advanced medications become available to meet the unmet medical needs of patients with CD, there is concern whether excessive prescriptions in real-world treatment practice in Japan could have a major impact on the direct costs associated with CD. Previous Japanese studies have reported high healthcare resource utilization (HRU) and costs associated with CD [17, 18]. While Yamabe et al [17] analyzed data from the 2012–2014 Japan National Health and Wellness Survey and reported mean annual per-patient direct costs to be ¥7,533,257; another claims data analyzed by Saito et al [18] from 2013–2016 reported median per-member per-year direct costs to be ¥1,957,320. Since ustekinumab was approved for CD in Japan in 2017 [11], the aforementioned studies lack information on its impact on clinical and economic burden. It is not only essential to understand the impact of advanced treatments on clinical conditions of CD, but also the impact on economic burden. Hence, in the current study we aimed to evaluate HRU and direct costs among Japanese patients on biologic therapy (including ustekinumab) for the treatment of CD.

Methods

Data source and study design

A mirror-image design was used for this study focusing on pre-post comparisons of medical resource used and claims cost estimate of one year before and after the biologic index date to understand the economic burden of biologics from the payer’s perspective in Japan (Fig 1). Retrospective claims data obtained from the Japan Medical Data Center (JMDC) database from 01 January 2010 to 30 September 2018 were analyzed. The database comprises corporate employees from medium to large scale companies and their dependents, and has been capturing inpatient, outpatient, pharmacy, and medical examination data for approximately 4.2 million individuals (at the time of analysis) since January 2005 [19]. The database has been widely used in health services research [20–22]. As long as an individual belongs to the Health Insurance Association, their medical consultation information can be tracked longitudinally, even if they attend multiple medical institutions or transfer to another hospital.
Information retrieved from the JMDC database was anonymized to protect patient privacy under the "Act on the Use of Numbers to Identify a Specific Individual in the Administrative Procedure". This study was approved by the sponsor’s internal approval committee in accordance with Japanese ethical and legal guidelines, Inflammatory Bowel Disease Research Concept Approval Team and Health Economics Review Board. The informed consent of patients was not required as per the Ethical Guidelines for Epidemiological Research issued by the Japanese Ministry of Health, Labor, and Welfare (MHLW), since the analysis were conducted on the retrospective anonymized claims database managed by JMDC. Reporting of claims data was based on International Society for Pharmacoeconomics and Outcomes Research guidelines [23].

**Patient selection**

Patients with a diagnosis of CD (International Classification of Diseases, 10th revision Clinical Modification K50.x) records within the timeframe of the evaluation period; at least one record of CD treatment (e.g. pharmacological agents, gastrointestinal procedure, enteral nutrition procedure and surgical procedure [S1–S3 Tables]) from the first CD diagnosis date; and 12 months of insurance coverage before and after the index date were included into the study (Fig 2). Since the highest incidence of CD is in the mean employment age, the current study uses claims data which is most appropriate to track the cost of illness and evaluate the cost driver to patients. Claims data can track the overall direct healthcare cost even when the patient is shifted to another hospitals or uses multiple facilities. Patients were followed-up within the timeframe period from the index date (earliest fill for CD-related medication) until dis-enrolment or end of study period whichever occurred first. Patients who did not have a record of CD-related treatment [24] after the CD diagnosis date were excluded.

Eligible patients were categorized into a non-biologic group i.e. patients without a biologic treatment record (e.g. 5-ASA, corticosteroids, and immunosuppressants) and a biologic group i.e. patients with a biologic treatment record (e.g. adalimumab, infliximab, and ustekinumab) (S1 Table); and further stratified by age as adults (≥18 years old) or children (<18 years old).
The patients were also segregated as per their insurance status into employees (adults), adult dependents, and children. This was performed because severe CD would hinder an employee’s ability to work, hence affecting enrolment status in the database. Employees who were enrolled were representative of the workforce, while adult dependents and children were representative of the general population.

**Study measures**

Claims information such as demographics (age and gender), insurance status, clinical characteristics (Charlson Comorbidity Index [CCI] and comorbid conditions), diagnosis (anatomical location of CD), dispensed drugs, gastrointestinal surgical interventions, and hospitalization records of patients were extracted from the database for analysis.

**Healthcare resource utilization and cost evaluation**

HRU measures such as outpatient visits, inpatient visits, surgery, enteral nutrition, and pharmacy claims, and cost claims associated with CD were obtained from the JMDC database. The medical resource used and cost estimate of one year before the biologic index date (first claim record of a biologic) and one year after the biologic index date was evaluated by the respective HRU categories. All costs were reported as Japanese Yen (¥) and were not adjusted for inflation because rates and prices have been flat for the past decade in Japan [25].

The cost of each resource was also reported over a follow-up period of 12, 24, and 36 months from the defined biologic index date. Biologic-prescribed patients with a continuous claims record for 12, 24, or 36 months were included in this analysis. For each resource category, the sum of costs of patients were divided by the sum of their follow-up time in months. Data were obtained only if the patients were in the health plan throughout the observation period.

**Statistical analysis**

Data for all study measures were summarized descriptively as mean values, SD, median, and range for continuous variables and frequency distribution for categorical variables. Baseline demographics and clinical characteristics were presented according to their assigned treatment
group. Comorbidities were assessed with the help of CCI prior to the index date for biologic users and throughout the entire enrolment period in JMDC for non-biologic users. CCI categorizes comorbidities of patients and has an associated weight (1 to 6), on the basis of adjusted risk of mortality or resource use, sum of all the weights provides a single comorbidity score for a patient. A score of zero means no comorbidities and higher the score, the more likely the predicted outcome will result in mortality or higher resource use. Overall cost of CD includes following parameters: inpatients (any medical resource charges that is related to hospital admission and direct primary care hospital cost), outpatients (medical resource charges at outpatient visits and visiting fees) and pharmacy cost. CCI and average costs per patient per month, by the type of medical resource utilization used (inpatients, outpatients, pharmacy), were reported as mean (SD) or median (interquartile range [IQR], which is the difference between the third and first quartiles).

**Results**

**Patient demographics**

After applying the inclusion and exclusion criteria, the included patients with CD (n = 3,496) were separated into two groups, biologic-treated (n = 1,783) and non-biologic treated (n = 1,713) (Fig 3).

The mean (SD) age of the overall cohort was 36.4 (13.2) years and majority of the patients were male (76.1%). Majority of the claims were from employed patients (72.3%), followed by dependent adults (21.6%), and children (6.1%). Many patients were also affected by comorbid conditions such as peptic ulcer disease (47.9%), chronic pulmonary disease (38.3%), and mild liver disease (24.6%) (Table 1).

**Healthcare resource utilization**

Biologic initiation was associated with a reduction in the mean (SD) number of inpatient visits per patient/month from 0.4 (1.0) to 0.2 (0.2), mean (SD) length of stay (LOS) from 5.3 (15.1) days to 2.5 (3.9) days, and mean (SD) number of outpatient visits per patient/month from 1.9 (4.3) to 1.1 (1.0). Similarly, biologic initiation was associated with a reduction in the overall number of hospitalizations and surgical procedures, but an increase in requirement of enteral nutrition (Table 2).

Table 3 shows the HRU 12, 24, and 36 months after biologic initiation. The 24 and 36 months refers to the time passed from the previous evaluation timepoint i.e. month 13 to 24 and month 25 to 36, respectively. Mean (SD) number of inpatient visits per patient/month were similar across all three time periods (0.14 [0.11] vs. 0.15 [0.13] vs. 0.15 [0.13]), while mean (SD) LOS decreased from 2.1 (2.8) days after 12 months to 1.8 (2.7) days after 24 months and increased to 2.2 (3.6) days after 36 months. Mean (SD) number of outpatient visits per patient/month reduced slightly from 1.1 (0.51) after 12 months to 1.0 (0.55) and 1.0 (0.53) after 24 and 36 months, respectively.

**Costs**

Biologic initiation was associated with a reduction in mean (SD) per patient/month inpatient costs from ¥276,164 (782,751) to ¥152,073 (357,579) and outpatient costs from ¥207,982 (840,357) to ¥204,157 (374,506). However, biologic initiation was associated with an increase in mean (SD) per patient/month pharmacy costs from ¥145,685 (739,873) to ¥245,894 (433,730) which led to an increase in total costs from ¥467,483 (1,700,960) to ¥497,289 (789,378) (Table 4).
Biologic initiation was associated with a reduction in mean (SD) per patient/month inpatient, outpatient, pharmacy, and total costs from 12 months to 24 months. However, all the cost categories showed an increase from 24 to 36 months post-initiation (Table 5).

Fig 3. Selection flow chart.

https://doi.org/10.1371/journal.pone.0254807.g003
Table 1. Demographics and characteristic of patients with CD.

| Characteristics                               | Non-biologics (n = 1,713) | Biologics (n = 1,783) | All patients (n = 3,496) |
|-----------------------------------------------|----------------------------|-----------------------|--------------------------|
| **Age, years (mean [SD])**                    | 38.8 (14.1)                | 34.2 (11.8)           | 36.4 (13.2)              |
| **Age category, years (n [%])**                |                            |                       |                          |
| < 18                                          | 99 (5.8)                   | 115 (6.4)             | 214 (6.1)                |
| 18–29                                         | 414 (24.2)                 | 615 (34.5)            | 1029 (29.4)             |
| 30–39                                         | 402 (23.5)                 | 502 (28.2)            | 904 (25.9)              |
| 40–49                                         | 383 (22.4)                 | 366 (20.5)            | 749 (21.4)              |
| 50–59                                         | 295 (17.2)                 | 151 (8.5)             | 446 (12.8)              |
| 60–69                                         | 109 (6.4)                  | 34 (1.9)              | 143 (4.1)               |
| ≥ 70                                          | 11 (0.6)                   | 0 (0)                 | 11 (0.3)                |
| **Gender, n (%)**                             |                            |                       |                          |
| Male                                          | 1,254 (73.2)               | 1,405 (78.8)          | 2,659 (76.1)            |
| Female                                        | 459 (26.8)                 | 378 (21.2)            | 837 (23.9)              |
| **Location of CD, n (%)**                     |                            |                       |                          |
| K50.0—small intestine                         | 236 (13.8)                 | 240 (13.5)            | 476 (13.6)              |
| K50.1—large intestine                         | 163 (9.5)                  | 168 (9.4)             | 331 (9.5)               |
| K50.8—both large and small intestine          | 226 (13.2)                 | 556 (31.2)            | 782 (22.4)              |
| K50.9—unspecified                             | 1088 (63.5)                | 819 (45.9)            | 1,907 (54.5)            |
| **Type of insurance, n (%)**                  |                            |                       |                          |
| Employee                                      | 1,235 (72.1)               | 1,293 (72.5)          | 2,528 (72.3)            |
| Dependent—Adult                               | 379 (22.1)                 | 375 (21.0)            | 754 (21.6)              |
| Dependent—Children                            | 99 (5.8)                   | 115 (6.4)             | 214 (6.1)               |
| **CCI Components, n (%)**                     |                            |                       |                          |
| Peptic ulcer disease                          | 745 (43.5)                 | 928 (52.0)            | 1,673 (47.9)            |
| Chronic pulmonary disease                     | 670 (39.1)                 | 670 (37.6)            | 1,340 (38.3)            |
| Mild liver disease                            | 413 (24.1)                 | 448 (25.1)            | 861 (24.6)              |
| Any malignancy, including lymphoma and leukemia, except malignant neoplasm of skin | 177 (10.3) | 137 (7.7) | 314 (9.0) |
| Rheumatic disease                             | 111 (6.5)                  | 131 (7.3)             | 242 (6.9)               |
| Congestive heart failure                      | 104 (6.1)                  | 68 (3.8)              | 172 (4.9)               |
| Cerebrovascular disease                       | 86 (5.0)                   | 51 (2.9)              | 137 (3.9)               |
| Diabetes without chronic complication         | 48 (2.8)                   | 42 (2.4)              | 90 (2.6)                |
| Renal disease                                 | 41 (2.4)                   | 49 (2.7)              | 90 (2.6)                |
| Peripheral vascular disease                   | 110 (6.4)                  | 47 (2.6)              | 157 (4.5)               |
| **CCI score**                                 | 1.8 (2.0)                  | 1.6 (1.7)             | 1.7 (1.9)               |
| Mean (IQR)                                    | 1.0 (0.0–2.0)              | 1.0 (1.0–2.0)         | 1.0 (0.0–2.0)           |

Abbreviations: CCI: Charlson-comorbidity Index; CD: Crohn’s Disease; IQR: Interquartile range; SD: Standard Deviation

*Clinical characteristics of patients were measured throughout patient’s enrolment in JMDC.

https://doi.org/10.1371/journal.pone.0254807.t001

**Discussion**

This is the first study to describe the demographics, HRU, and direct costs before and after biologic initiation in CD-affected Japanese patients, using claims data. The major strengths of this study are database capture of the entire CD treatment pathway including all hospitalizations, outpatient visits, and pharmacy dispensing, resulting in inclusive HRU and cost estimation; and evaluation of HRU and direct medical costs in patients on ustekinumab, which was approved for treatment of CD in Japan in 2017. The higher prevalence of CD in males and
individuals aged 18–50 years old in the current study is consistent with previous research conducted through national surveys and hospital or claims data analyses [4, 17, 18, 26]. Murakami et al [4] has posited smoking to be the reason for male predominance in CD, as smoking (both active and passive) are risk factors for CD [27, 28]. The current study also report comorbid conditions such as peptic ulcer, chronic pulmonary and mild liver disease that have direct impact on the claims cost and resource utilization during CD treatment. The baseline data of comorbid conditions also helps in data interpretation.

Biologic initiation was associated with a 11% increase in enteral nutrition. However, this could be attributed to a unique practice recommended in Japanese clinical treatment guidelines [8] wherein enteral nutrition is recommended for mild CD patients before starting conventional drug treatment, for moderate to severe patients to control food intake, for those who may not fully respond to biologic treatment, and for those who received surgery. Moreover, Japanese studies have reported satisfactory remission induction rate and maintenance rates

| Table 2. CD-related HRU one year before and one year after biologic index date. |
|-----------------------------------------------|
| Number of visits per CD patient/ month        |
| Before biologics (n = 1,783)                  |
| After biologics (n = 1,783)                   |
| Inpatient visits                              |
| Mean (SD)                                     |
| 0.36 (0.97)                                   |
| Median (IQR)                                  |
| 0.16 (0.08–0.25)                              |
| Length of stay, days                          |
| Mean (SD)                                     |
| 5.34 (15.15)                                  |
| Median (IQR)                                  |
| 1.89 (0.90–3.87)                              |
| Outpatient visits                             |
| Mean (SD)                                     |
| 1.88 (4.27)                                   |
| Median (IQR)                                  |
| 0.99 (0.68–1.46)                              |
| Number of events                              |
| Before biologics (n = 1,783)                  |
| After biologics (n = 1,783)                   |
| Hospitalization                               |
| 578                                           |
| Surgical procedures                           |
| 308                                           |
| Enteral nutrition                             |
| 446                                           |

| Table 3. CD-related HRU 12 months, 24 months 36 months after biologic index date. |
|-----------------------------------------------|
| Number of visits per CD patient/ month        |
| 12 months after biologic index date (n = 1,363) |
| 24 months after biologic index date (n = 1,100) |
| 36 months after biologic index date (n = 851)  |
| Inpatient visits                              |
| Mean (SD)                                     |
| 0.14 (0.11)                                   |
| Median (IQR)                                  |
| 0.08 (0.08–0.16)                              |
| Length of stay, days                          |
| Mean (SD)                                     |
| 2.15 (2.85)                                   |
| Median (IQR)                                  |
| 1.23 (0.49–2.51)                              |
| Outpatient visits                             |
| Mean (SD)                                     |
| 1.08 (0.51)                                   |
| Median (IQR)                                  |
| 0.99 (0.74–7.23)                              |

The 24 and 36 months refers to the time passed from the previous evaluation timepoint i.e. month 13 to 24 and month 25 to 36, respectively.

Abbreviations: CD: Crohn’s Disease; HRU: Healthcare Resource Utilization; IQR: Interquartile range; SD: Standard Deviation.

https://doi.org/10.1371/journal.pone.0254807.t002

https://doi.org/10.1371/journal.pone.0254807.t003
Further studies are needed to understand the initiation of biologics and the increased burden of enteral nutrition in Japan. Biologic initiation was associated with a reduction in inpatient visits by 53%, LOS by 54%, surgical procedures by 40%, inpatient costs by 45%, outpatient visits by 39%, and outpatient costs by 2%. However, biologic initiation was associated with an increase in pharmacy costs by 40% and total costs by 6%. Similarly, other studies in various healthcare systems have associated biologic initiation with a reduction in inpatient and outpatient visits and their associated costs; however, an increase in pharmacy costs, most likely due to biologic prescriptions, resulted in greater total direct costs compared with pre-biologic expenses [30–32]. Although the present study did not distinguish between biologic and other drug-related costs, Saito et al. [18] analyzed patient data (2013–2016) from the JMDC database and reported the total CD-related costs to be ¥7,139,604,830, with anti-TNFα agents accounting for 59.5% of the total costs.

### Table 4. Direct costs 12 months before and after biologic initiation.

| Cost per CD patient/ month (¥) | 12 months before biologics (n = 1,783) | 12 months after biologics (n = 1,783) |
|-------------------------------|----------------------------------------|--------------------------------------|
| **Inpatient**                 |                                        |                                      |
| Mean (SD)                     | 276,164 (782,751)                      | 152,073 (357,579)                    |
| Median (IQR)                  | 99,122 (48,406–211,180)               | 75,674 (33,372–168,414)              |
| **Outpatient**                |                                        |                                      |
| Mean (SD)                     | 207,982 (840,357)                      | 204,157 (374,506)                    |
| Median (IQR)                  | 27,547 (10,807–97,879)                | 183,219 (89,529–247,517)             |
| **Pharmacy**                  |                                        |                                      |
| Mean (SD)                     | 145,685 (739,873)                      | 245,894 (433,730)                    |
| Median (IQR)                  | 2,568 (1,085–13,231)                  | 183,400 (155,623–241,753)            |
| **Total costs**               |                                        |                                      |
| Mean (SD)                     | 467,483 (1,700,960)                    | 497,289 (789,378)                    |
| Median (IQR)                  | 98,724 (25,316–312,995)               | 397,200 (299,527–539,531)            |

**Abbreviations:** CD: Crohn’s Disease; IQR: Interquartile range; SD: Standard Deviation.

https://doi.org/10.1371/journal.pone.0254807.t004

### Table 5. Direct costs 12, 24, and 36 months after biologic initiation.

| Cost per CD patient/ month (¥) | 12 months after biologic index date (n = 1,363) | 24 months after biologic index date (n = 1,100) | 36 months after biologic index date (n = 851) |
|-------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| **Inpatient**                 |                                               |                                               |                                               |
| Mean (SD)                     | 123,189 (136,791)                            | 106,559 (133,295)                            | 126,418 (162,151)                            |
| Median (IQR)                  | 79,219 (36,696–154,382)                      | 57,542 (22,551–146,764)                      | 57,106 (23,227–189,959)                      |
| **Outpatient**                |                                               |                                               |                                               |
| Mean (SD)                     | 178,480 (109,500)                            | 165,394 (108,567)                            | 170,611 (107,930)                            |
| Median (IQR)                  | 183,228 (94,818–239,407)                     | 167,541 (76,648–226,998)                     | 174,158 (102,970–235,308)                     |
| **Pharmacy**                  |                                               |                                               |                                               |
| Mean (SD)                     | 193,320 (71,326)                             | 170,162 (73,702)                             | 173,778 (79,007)                             |
| Median (IQR)                  | 176,808 (153,713–222,501)                    | 153,355 (132,907–201,113)                    | 158,031 (132,113–214,273)                     |
| **Total costs**               |                                               |                                               |                                               |
| Mean (SD)                     | 423,005 (182,367)                            | 360,132 (181,575)                            | 370,774 (190,366)                            |
| Median (IQR)                  | 392,524.1 (305,029.3–510,890)                | 334,253.0 (250,486.9–464,974)                | 347,881 (257,216–472,191)                     |

Patients who had records available for the complete 12, 24, or 36 months were included in the respective groups.

**Abbreviations:** CD: Crohn’s Disease; IQR: Interquartile range; SD: Standard Deviation.

https://doi.org/10.1371/journal.pone.0254807.t005
costs. Studies from the Netherlands [33] and United States [34, 35] have also reported biologic-related costs to be a major driver of total costs.

We also evaluated HRU and direct costs 12, 24, and 36 months after biologic initiation. Here, compared to 12-month data, HRU and costs seemed to be similar or lower after 24 months of follow-up. However, HRU and direct costs after 36 months of follow-up were higher than the 24-month data, suggesting that some patients undergoing biologic treatment may not respond optimally after 24 months of treatment, and hence may have to switch treatment or undergo surgery to manage CD. This seems plausible since previous research has reported a reduction in persistence with biologics as time passes, with a wide range in the rate of non-persistence due to treatment discontinuation or switching [36–39].

Japanese clinical guidelines recommend biologics for treatment of moderate to severe and severe CD [7, 40]. Hence, real-world treatment practice may reflect this recommendation, as a higher proportion of patients on biologics in the current study had CD in both the small and large intestine compared with patients not on biologics (31.2% vs. 13.2%). Complications such as fistulae have an adverse impact on a patient’s health-related quality of life (HRQoL) [7] and also result in greater median costs than those without fistulae ($10,868 vs. $6,268), primarily due to hospitalization and surgery [41]. Hence, optimally managing fistulae quickly is required. Infliximab has been reported to significantly reduce hospitalizations, LOS, and surgeries (P < 0.05) in patients with fistulizing CD compared with placebo treatment [42]. Moreover, a Markov model by Lindsay et al [43] showed an eight-week scheduled maintenance treatment with infliximab to be cost-effective in patients with active luminal or fistulizing CD. Thus, usage of biologics early could potentially reduce disease progression and HRU as well as translate into long-term cost savings.

Patients with inflammatory bowel disease (IBD) experience lower HRQoL; higher absenteeism, presenteeism, and work and activity impairment; higher HRU; and higher direct and indirect costs compared with the general population [17, 44–47]. However, comparing IBD with other diseases may reveal the true burden of IBD on society. Although cancer is the leading cause of death in Japan (death rate 298.3 per 100,000 people) [48], cancer-affected adults have reported higher HRQoL and lower work and activity impairment than IBD-affected adults in Japan [49]. Moreover, the total mean per-patient/month costs for CD are also higher than another intractable disease such as systemic lupus erythematosus (¥497,289 [current study] vs. ¥84,751 [Miyaizaki et al] [20]), thus highlighting the huge burden of IBD on a patient’s daily life. Biologics have been reported to induce and maintain clinical remission in Japanese patients with moderate to severe CD [50] as well as reduce the burden of IBD by improving HRQoL, reducing work and activity impairment, and decreasing HRU across varying healthcare systems [30, 50–56]. Although biologic initiation is associated with higher direct costs, as observed in our study, biologic initiation may reduce indirect costs due to its positive impact on work productivity. This is especially relevant in Japan where patients with IBD have reported facing difficulties at work due to IBD, resulting in poor performance, lack of career advancement, and workplace alienation [57]. Moreover, patients with IBD have a higher unemployment rate compared with the general population (12.3% vs. 3.2%) [58]. Therefore, biologics may help to increase work productivity as well as reduce the unemployment rate, resulting in lower indirect costs. Unfortunately, the effect of biologics on indirect costs in Japan has not been evaluated. Further research could shed light on this aspect.

Limitations
This study has several limitations. First, the JMDC database does not include clinical examination results or physician-assessed severity, which could have enabled stratification of treatment
based on disease severity. Second, as the database records insurance claims for employees of medium- to large-scale companies and their dependents only, this study could not assess data of patients who are not covered in the database. Third, as the database is linked to employment status, the elderly are underrepresented in the database. Therefore, the results of this study may not be applicable to every age group. Moreover, since cost data is variable in nature, a larger sample size may be required. A limitation of assessing costs in pre- and post- study designs is that costs incurred due to failure of treatment A but before initiating treatment B, are poorly assessed. Although patients with severe disease often incur higher costs [20], we reported mean cost per patient/month since we were unable to assess treatment costs based on disease severity. However, it is possible to provide an expenditure estimate for payers since the JMDC allows for projection of nationwide totals [59]. A major limitation of the study is the lack of evaluation of work productivity and activity impairment and associated indirect costs, which have been reported to be high in Japanese patients with CD [17]. We were also unable to capture the costs for patients who require long-term care as these costs are not captured in the database. Evaluation of the impact of biologics on indirect costs may reveal the true effect of biologics on society. Finally, due to the cross-sectional nature of the data, causal inferences cannot be made from the results.

Conclusion

Our study demonstrated that biologic therapy in patients with CD was associated with a reduction in HRU and related costs, and a slight increase in total pharmacy costs compared with their treatment period before biologic therapy. Use of effective biologic therapies for CD treatment can gradually reduce the economic burden on government that provides financial assistance to patients with CD in Japan. Furthermore, evaluation of indirect costs in the future may reveal the true impact of biologics on payers, and may help in appropriate allocation of resources to reduce the burden on both patients and payers.

Supporting information

S1 Table. Pharmacological agents.
(DOCX)

S2 Table. Enteral nutrition procedures.
(DOCX)

S3 Table. Surgical procedures.
(DOCX)

Acknowledgments

The authors acknowledge Leo J. Philip Tharappel and Bernard Tulsi (Siro Clinpharm Pvt Ltd.) for medical writing and editorial assistance.

Author Contributions

Conceptualization: Celine Miyazaki, Nagano Katsumasa, Yan Fang Liu.
Data curation: Celine Miyazaki, Nagano Katsumasa, Kuan Chih Huang, Yan Fang Liu.
Formal analysis: Kuan Chih Huang, Yan Fang Liu.
Funding acquisition: Celine Miyazaki.
Investigation: Celine Miyazaki, Nagano Katsumasa.
Methodology: Celine Miyazaki.
Project administration: Celine Miyazaki.
Software: Kuan Chih Huang, Yan Fang Liu.
Supervision: Celine Miyazaki.
Writing – original draft: Celine Miyazaki.
Writing – review & editing: Celine Miyazaki, Nagano Katsumasa, Kuan Chih Huang, Yan Fang Liu.

References
1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017; 389:1741–55.  
https://doi.org/10.1016/S0140-6736(16)31711-1 PMID: 27914655
2. Lauriot dit Prevost C, Azaahel M, Nachury M, Branche J, Gerard R, Wils P, et al. Bowel damage and disability in Crohn’s disease: a prospective study in a tertiary referral centre of the Lémann Index and Inflammatory Bowel Disease Disability Index. Aliment Pharmacol Ther. 2020; 51:889–98. https://doi.org/10.1111/apt.15681 PMID: 32221985
3. Crohn’s disease [designated intractable disease 96]: Japan Intractable Diseases Information Center; 2020 [https://www.nanbyou.or.jp/entry/81].
4. Murakami Y, Nishiwaki Y, Oba MS, Asakura K, Ohfuji S, Fukushima W, et al. Estimated prevalence of ulcerative colitis and Crohn's disease in Japan in 2014: an analysis of a nationwide survey. J Gastroenterol. 2019; 54:1070–7. https://doi.org/10.1007/s00535-019-01603-8 PMID: 31309327
5. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016; 14:111–9. PMID: 27175111
6. Yokoyama K, Yamazaki K, Katafuchi M, Ferchichi S. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn’s Disease Treated with Adalimumab or Infliximab. Adv Ther. 2016; 33:1947–63. https://doi.org/10.1007/s12325-016-0406-6 PMID: 27664107
7. Okabayashi S, Kobayashi T, Hibi T. Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns? J Anus Rectum Colon. 2020; 4:1–13. https://doi.org/10.23922/jarc.2019-003 PMID: 32002471
8. Criteria for diagnosis and treatment of ulcerative colitis / Crohn’s disease [In Japanese]. Tokyo, Japan: Ministry of Health, Labor and Welfare; 2020.
9. Report on the Deliberation Results Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare 2002.
10. Abbott Japan and Eisai Receive Approval for Additional Indications of Humira®, a Fully Human Anti-TNFα Monoclonal Antibody, for the Treatment of Crohn’s Disease and Ankylosing Spondylitis 2010 [https://www.eisai.com/news/pdf/enews201059pdf.pdf].
11. Report on the Deliberation Results. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare; 2017.
12. Pineton de Chambrun G, Peyrin-Biroulet L, Lernmann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010; 7:15–29. https://doi.org/10.1038/nrgastro.2009.203 PMID: 19949430
13. Froslie KF, Jahnsen J, Moum BA, Vatn MH, Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133:412–22. https://doi.org/10.1053/j.gastro.2007.05.051 PMID: 17681162
14. Intractable disease measures Tokyo, Japan: Ministry of Health, Labor, and Welfare; [https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_ryoukou/kenkou/nanbyou/index.html].
15. Takemura S, Sone T. Research and development on intractable & rare diseases in Japan: Contribution of the National Institute of Public Health to research program management. Journal of the National Institute of Public Health. 2019; 68:45–54.
16. Aging situation: Cabinet Office; 2018 [https://www8.cao.go.jp/kourei/whitepaper/w-2018/gaiyou/pdf/1s1s.pdf].
17. Yamabe K, Liebert R, Flores N, Pashos CL. Health-related quality of life outcomes and economic burden of inflammatory bowel disease in Japan. Clinicoecon Outcomes Res. 2019; 11:221–32. https://doi.org/10.2147/CEOR.S179892 PMID: 30881067
18. Saito S, Nakazawa K, Suzuki K, Ishikawa T, Akazawa K. Paradigm Shift of Healthcare Cost for Patients with Inflammatory Bowel Diseases: A Claims Data-Based Analysis in Japan. Gastrointest. 2019; 1:120–8.
19. JMDC Claims Database: JMDC; 2020 [https://www.jmdc.co.jp/en/jmdc-claims-database].
20. Miyazaki C, Sruamsiri R, Mahlich J, Jung W. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study, J Med Econ. 2020; 23:786–99. https://doi.org/10.1080/13696998.2020.1740236 PMID: 32149541
21. Mahlich J, Tsukazawa S, Wiegand F. Estimating Prevalence and Healthcare Utilization for Treatment-Resistant Depression in Japan: A Retrospective Claims Database Study. Drugs Real World Outcomes. 2018; 5:35–43. https://doi.org/10.1007/s40801-017-0126-5 PMID: 29185233
22. Sruamsiri R, Iwasaki K, Tang W, Mahlich J. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database. BMC Dermatol. 2018; 18:5. https://doi.org/10.1186/s12895-018-0074-0 PMID: 29996929
23. Motheral B, Brooks J, Clark MA, Crown WH, Davey P, Hutchins D, et al. A checklist for retrospective database studies—report of the ISPOR Task Force on Retrospective Databases. Value Health. 2003; 6:90–7. https://doi.org/10.1046/j.1524-4733.2003.00242.x PMID: 12641858
24. Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018; 53:305–53. https://doi.org/10.1007/s00535-018-1439-1 PMID: 29429045
25. Measures of Underlying Inflation Tokyo, Japan: Bank of Japan; 2020 [https://www.boj.or.jp/en/research/research_data/cpi/index.htm/].
26. Yao T, Matsu T, Hiwatashi N. Crohn’s disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum. 2000; 43:S85–93. https://doi.org/10.1007/BF02237231 PMID: 11052483
27. Kondo K, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Ito K, et al. The association between environmental factors and the development of Crohn’s disease with focusing on passive smoking: A multicenter case-control study in Japan. PLoS One. 2019; 14:e0216429. https://doi.org/10.1371/journal.pone.0216429 PMID: 31173593
28. Berkowitz L, Schultz BM, Salazar GA, Pardo-Roa C, Sebastian VP, Alvarez-Lobos MM, et al. Impact of Cigarette Smoking on the Gastrointestinal Tract Inflammation: Opposing Effects in Crohn’s Disease and Ulcerative Colitis. Front Immunol. 2018; 9:74. https://doi.org/10.3389/fimmu.2018.00074 PMID: 29441064
29. Hiwatashi N. Enteral nutrition for Crohn’s disease in Japan. Dis Colon Rectum. 1997; 40:S48–53. https://doi.org/10.1007/BF02237231 PMID: 9378012
30. Saro C, Ceballos D, Munoz F, De la Coba C, Aguilar MD, Lazaro P, et al. Resources Utilization and Costs the Year Before and After Starting Treatment with Adalimumab in Crohn’s Disease Patients. Inflamm Bowel Dis. 2015; 21:1631–40. https://doi.org/10.1097/MIB.0000000000000413 PMID: 25961910
31. Miot J, Smith S, Bhimsan N. Resource use and cost of care with biologics in Crohn’s disease in South Africa: a retrospective analysis from a payer perspective. Int J Clin Pharm. 2016; 38:880–7. https://doi.org/10.1007/s11966-016-0304-7 PMID: 27118462
32. Perera S, Yang S, Stott-Miller M, Brady J. Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Ulcerative Colitis and Crohn’s Disease. J Health Econ Outcomes Res. 2018; 6:96–112. PMID: 32685575
33. van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut. 2014; 63:72–9. https://doi.org/10.1136/gutjnl-2012-303376 PMID: 23513575
34. Park KT, Colletti RB, Rubin DT, Sharma BK, Thompson A, Krueger A. Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn’s Disease in the United States. Am J Gastroenterol. 2016; 111:15–23. https://doi.org/10.1038/aig.2015.207 PMID: 26195179
35. Yu H, MacIsaac D, Wong JJ, Sellers ZM, Wren AA, Bensen R, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther. 2018; 47:364–70. https://doi.org/10.1111/apt.14430 PMID: 29164650
36. Khan S, Rupniestwka E, Neighbors M, Singer D, Chiariappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in Japan.
37. Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, et al. Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy. Inflamm Bowel Dis. 2019; 25:1417–27. https://doi.org/10.1093/ibd/izz001 PMID: 30839057

38. Jung YS, Han M, Park S, Cheon JH. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study. Dig Dis Sci. 2020; 65:1436–44. https://doi.org/10.1007/s10620-019-05867-1 PMID: 31677070

39. Mevius A, Brandes A, Hardstock F, Wilke T, Ratsch BA, Orzechowski HD, et al. Persistence with Biologic Treatment in Patients with Inflammatory Bowel Disease: A German Claims Data Analysis. Digestion. 2019:1–11. https://doi.org/10.1159/000503859 PMID: 31639807

40. Ueno F, Matsui T, Matsumoto T, Matsuoka K, Watanabe M, Hibi T, et al. Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan. J Gastroenterol. 2013; 48:31–72. https://doi.org/10.1002/j.1578-1450.2013.tb00803.x PMID: 23090001

41. Cohen RD, Waters HC, Tang B, Rahman MI. Effects of fistula on healthcare costs and utilization for patients with Crohn’s disease treated in a managed care environment. Inflamm Bowel Dis. 2008; 14:1707–14. https://doi.org/10.1002/ibd.20530 PMID: 18618630

42. Lichtenstein GR, Yan S, Baia M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology. 2005; 128:862–9. https://doi.org/10.1053/j.gastro.2005.01.048 PMID: 15825070

43. Lindsay J, Punekar YS, Morris J, Chung-Fay G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease—modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008; 28:76–87. https://doi.org/10.1111/j.1365-2036.2008.03709.x PMID: 18410558

44. Matsumoto T, Yanai S, Toya Y, Ueno M, Nakamura S. Internet-orientated Assessment of QOL and Actual Treatment Status in Japanese Patients with Inflammatory Bowel Disease: The 3I survey. J Crohns Colitis. 2015; 9:477–82. https://doi.org/10.1093/ecto-jcc/jv052 PMID: 25814388

45. Zand A, van Deeren WK, Inserra EK, Hall L, Kane E, Centeno A, et al. Presenteeism in Inflammatory Bowel Diseases: A Hidden Problem with Significant Economic Impact. Inflamm Bowel Dis. 2015; 21:1623–30. https://doi.org/10.1097/MIB.0000000000000399 PMID: 26070004

46. Pilon D, Ding Z, Muser E, Obando C, Voelker J, Manceur AM, et al. Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population. Curr Med Res Opin. 2020; 36:1285–94. https://doi.org/10.1080/03007995.2020.1771293 PMID: 32427006

47. Park KT, Ehrlich OG, Allen JI, Meadows P, Sziczethy EM, Henrichsen K, et al. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation. Inflamm Bowel Dis. 2020; 26:1–10. https://doi.org/10.1093/ibd/izz104 PMID: 31112238

48. Deaths Tokyo, Japan: Director-general for statistics and information policy, Ministry of Health, Labour and Welfare of Japan; 2017 [https://www.mhlw.go.jp/kouyouyo/youran/youran1/shibou.pdf.

49. The Global Health and Wellness Report: Findings from the National Health and Wellness Survey [NHWS]. Kantar Health; 2017.

50. Sands BE, Han C, Naessens D, Gasink C, Jacobstein D, Gao LL, et al. Ustekinumab Improves Productivity and Reduces Work Limitation of Patients With Moderate to Severe Crohn’s Disease: Results From Three Phase 3 Clinical Trials. Am J Gastroenterol. 2018; 113:S352.

51. Waters HC, Vanderpoel JE, Nejadnik B, McKenzie RS, Lunacsek OE, Lennert BJ, et al. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease. J Med Econ. 2012; 15:45–52.

52. Xu J, Lin H, Feng X, Tang M, Shen J, Ran Z. Different therapeutic approaches on quality of life in patients with inflammatory bowel disease. BMC Gastroenterol. 2014; 14:199. https://doi.org/10.1186/s12876-014-0199-5 PMID: 25421821

53. Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010; 32:1228–39. https://doi.org/10.1111/j.1365-2036.2010.04466.x PMID: 20955442
55. Sands BE, Han C, Gasink C, Jacobstein D, Szapary P, Gao LL, et al. The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease. J Crohns Colitis. 2018; 12:883–95. https://doi.org/10.1093/ecco-jcc/jjy055 PMID: 29726939

56. Obando C, Ding Z, Muser E, Vaidya N, Qiang W, Sun X, et al. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States. Adv Ther. 2020; 37:2127–43. https://doi.org/10.1007/s12325-020-01276-3 PMID: 32193810

57. Ito M, Togari T, Park MJ, Yamazaki Y. Difficulties at work experienced by patients with inflammatory bowel disease (IBD) and factors relevant to work motivation and depression. Jpn J Health & Human Ecology. 2008; 74:290–310.

58. Mahlich J, Matsuoka K, Nakamura Y, Sruamsiri R. The relationship between socio-demographic factors, health status, treatment type, and employment outcome in patients with inflammatory bowel disease in Japan. BMC Public Health. 2017; 17:623. https://doi.org/10.1186/s12889-017-4516-0 PMID: 28676039

59. Shimizu E, Kawahara K. Assessment of medical information databases to estimate patient numbers. Jpn J Pharmacoepidemiol. 2014; 19:1–11.